Table 1.
COVID-19 vaccine candidates in clinical and preclinical development [51].
| Vaccine Code/Name | Vaccine Type | Developer | Delivery Route | Doses | Development Stage |
|---|---|---|---|---|---|
| ChAdOx1-S (AZD1222) | Simian adenovirus vector (spike) |
University of Oxford | IN | 1 or 2 Day 0 + 28 |
Clinical trial NCT04816019 Phase I |
| DelNS1-2019-nCoV-RBD-OPT1 | Influenza virus vector |
University of Hong Kong Xiamen University Beijing Wantai Biological |
IN | 2 Day 0 + 28 |
Clinical trial ChiCTR2000039715 Phase II |
| COVI-VAC | Live attenuated SARS-CoV-2 virus |
Codaginex Serum Institute of India |
IN | 1 or 2 Day 0 or Day 0 + 28 |
Clinical trial NCT04619628 Phase I |
| CIGB-669 | Protein subunit |
Centre for genetic Engineering and Biotechnology (CIGB) | IN | 3 Day 0 + 14 + 28 or Day 0 + 28 + 56 |
Clinical trial RPCEC00000345 Phase I/II |
| AdCOVID | Adenovirus vector |
Altimmune, Inc. | IN | 1 Day 0 |
Discontinued In Clinical trial NCT04679909 Phase I |
| Razi Cov Pars | Protein subunit |
Razi Vaccine and Serum Research Institute | IM and IN |
3 Day 0 + 21 + 51 |
Clinical trial IRCT20201214049709N2 Phase II |
| BBV154 | Simian adenovirus vector |
Bharat Biotech International Limited | IN | 1 Day 0 |
Clinical trial NCT04751682 Phase I |
| MV-014-212 | Live attenuated RSV virus |
Meissa Vaccines, Inc. | IN | 1 Day 0 |
Clinical trial NCT04798001 Phase I |
| Live rNDV vector vaccine | Inactivated virus |
Laboratorio Avi-Mex | IM or IN |
2 Day 0 + 21 |
Clinical trial NCT04871737 Phase I |
| PIV5 | Viral vector | CyanVac LLC | IN | 1 Day 0 |
Clinical trial NCT04954287 Phase I |
| COVAC-ND | Viral vector | Utrecht UniversityWageningen Bioveterinary Research Intravacc |
IN | NA | Preclinical |
| Liposomal formulation with GLA/3M052 adjs. | Protein subunit |
University of Virginia | IN | NA | Preclinical |
| Ad 5 vector | Viral vector | University of Helsinki University of Eastern Finland | IN | NA | Preclinical |
| Live viral vector based on attenuated Influenza virus | Viral vector | BiOCAD IEM |
IN | NA | Preclinical |
| Recombinant vaccine based on Influenza A virus | Viral vector | FBRI SRC VB VECTOR Rospotrebnadzor Koltsovo | IN | NA | Preclinical |
| rNDV-LS1-FARVET expressing RBD protein: rNDV-LS1-HN-RBD/SARS-CoV-2 | Viral vector | Farmacológicos Veterinarios SAC |
IN | NA | Preclinical |
| rNDV-LS1-FARVET expressing S1 protein: rNDV-LS1-S1-F/SARS-CoV-2 | Viral vector | Farmacológicos Veterinarios SAC |
IN | NA | Preclinical |
| mRNA in IN delivery system | mRNA | eTheRNA | IN | NA | Preclinical |